Trial NCT01115803

View at ClinicalTrials.gov 
Org. Study IDs: 12531
Secondary IDs: I3G-MC-JGCB

Last trial update was posted on 2019-02-05

MeSH Interventions

Erlotinib Hydrochloride Everolimus

MeSH Conditions

Carcinoma Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Neoplasm Metastasis Neuroendocrine Tumors

Other Conditions

Carcinoma, Non-small Cell Lung Metastases, Neoplasm Renal Cell Carcinoma

Stopping Reasons

Primary objective has been met; safety and pharmacokinetics have been characterized.

Limitations And Caveats

Study terminated early. Dose confirmation, Part B, was not initiated.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID